Source: Eur Respir J 2011; 37: 1352-1359
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Holgate S.T., Noonan M., Chanez P., Busse W., Dupont L., Pavord I., Hakulinen A., Paolozzi L., Wajdula J., Zang C., Nelson H., Raible D.. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011; 37: 1352-1359

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 “Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial Source: ERJ Open Res, 7 (3) 00738-2020; 10.1183/23120541.00738-2020 Year: 2021 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 Efficacy of fluticasone on cough: a randomised controlled trial Source: Eur Respir J 2005; 25: 147-152 Year: 2005 Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD Year: 2012 A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012 Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? Source: ERJ Open Res 2016: 00055-2016 Year: 2016 Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012 Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Source: Eur Respir J 2016; 47: 981-984 Year: 2016 Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006